Differences in the biologic activity of 2 novel MEK inhibitors revealed by 18F-FDG PET: analysis of imaging data from 2 phase I trials
F Kraeber-Bodéré, T Carlier… - Journal of Nuclear …, 2012 - Soc Nuclear Med
Two mitogen-activated protein kinase kinase (MAPK2, also known as MEK) inhibitors were
assessed with 18F-FDG PET in separate phase I clinical studies, clearly illustrating the …
assessed with 18F-FDG PET in separate phase I clinical studies, clearly illustrating the …
[HTML][HTML] Evaluation of the therapeutic efficacy of a MEK inhibitor (TAK-733) using 18F-fluorodeoxyglucose-positron emission tomography in the human lung xenograft …
S Ishino, H Miyake, P Vincent, I Mori - Annals of Nuclear Medicine, 2015 - Springer
Objective The aim of this study was to evaluate the potential of 18 F-fluorodeoxyglucose-
positron emission tomography (18 F-FDG-PET) for monitoring the therapeutic efficacy of TAK …
positron emission tomography (18 F-FDG-PET) for monitoring the therapeutic efficacy of TAK …
[HTML][HTML] Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [18F] FDG-PET imaging combined with proteomic approaches
T Tegnebratt, E Ruge, S Bader, N Ishii, S Aida… - Ejnmmi Research, 2014 - Springer
Background Inhibition of mitogen-activated protein kinase (MEK, also known as MAPK2,
MAPKK), a key molecule of the Ras/MAPK (mitogen-activated protein kinase) pathway, has …
MAPKK), a key molecule of the Ras/MAPK (mitogen-activated protein kinase) pathway, has …
[HTML][HTML] [18 F]FDG-PET imaging is an early non-invasive pharmacodynamic biomarker for a first-in-class dual MEK/Raf inhibitor, RO5126766 (CH5126766), in …
T Tegnebratt, L Lu, L Lee, V Meresse, J Tessier, N Ishii… - EJNMMI research, 2013 - Springer
Background Positron emission tomography (PET) with [2-18 F]-2-fluoro-2-deoxy-D-glucose
([18 F] FDG-PET) was acquired at multiple time-points a) to monitor the early response to …
([18 F] FDG-PET) was acquired at multiple time-points a) to monitor the early response to …
Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET
JR Tseng, KW Kang, M Dandekar… - Journal of Nuclear …, 2008 - Soc Nuclear Med
The purpose of this study was to evaluate the efficacy of CE-355621, a novel antibody
against c-Met, in a subcutaneous U87 MG xenograft mouse model using 18F-FDG small …
against c-Met, in a subcutaneous U87 MG xenograft mouse model using 18F-FDG small …
18 F-FLT-PET for response evaluation of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with solid tumors
I Desar, R Gilles, C Van Herpen… - World Journal of …, 2012 - thieme-connect.com
Selumetinib (AZD6244, ARRY-142886) is a potent, selective, uncompetitive inhibitor of MEK
1/2, part of the RAF/MEK/ERK protein kinase signal cascade, which is responsible for tumor …
1/2, part of the RAF/MEK/ERK protein kinase signal cascade, which is responsible for tumor …
Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma
RJ Schmitt, SM Kreidler, DH Glueck… - Nuclear medicine …, 2016 - journals.lww.com
Purpose Metabolic response to treatment measured by fluorine-18 fluorodeoxyglucose (18 F-
FDG) PET has prognostic implications in many cancers. This study investigated the …
FDG) PET has prognostic implications in many cancers. This study investigated the …
A first-in-human phase 1 study to evaluate the MEK1/2 inhibitor GDC-0973 administered daily in patients with advanced solid tumors
L Rosen, P LoRusso, WW Ma, J Goldman, A Weise… - Cancer Research, 2011 - AACR
Abstract Background: The RAS/RAF/MEK/ERK signaling pathway, which is deregulated in a
variety of tumor types, plays a major role in mediating cell growth and differentiation. GDC …
variety of tumor types, plays a major role in mediating cell growth and differentiation. GDC …
Phase I (Ph) safety, pharmacodynamic (PD), and pharmacokinetic (PK) trial of a pure MEK inhibitor (i), RO4987655, in patients with advanced/metastatic solid tumor.
S Leijen, MR Middleton, P Tresca… - Journal of Clinical …, 2011 - ascopubs.org
3017 Background: Mutations of Ras/Raf lead to a sustained and constitutive activation of
ERK pathway. MEK1/2 is the only enzyme that activates ERK1/2; consequently MEK1/2 is a …
ERK pathway. MEK1/2 is the only enzyme that activates ERK1/2; consequently MEK1/2 is a …
Synthesis of the PET tracer 124I-trametinib for MAPK/ERK kinase distribution and resistance monitoring
EC Pratt, E Isaac, EP Stater, G Yang… - Journal of Nuclear …, 2020 - Soc Nuclear Med
Trametinib is an extremely potent allosteric inhibitor of mitogen-activated protein kinase
(MAPK)/extracellular-signal–regulated kinase (ERK)(MEK) 1/2, which has been approved …
(MAPK)/extracellular-signal–regulated kinase (ERK)(MEK) 1/2, which has been approved …
Related searches
- fdg pet mek inhibitor
- mek inhibitors biologic activity
- solid tumor mek inhibitor
- fdg pet evaluation of efficacy
- fdg pet proteomic approaches
- evaluation of efficacy mek inhibitor
- fluorodeoxyglucose positron mek inhibitor
- proteomic approaches mek inhibitor
- emission tomography mek inhibitor
- solid tumors response evaluation
- flt pet response evaluation
- solid tumors flt pet
- therapeutic efficacy mek inhibitor